The introduction of plasmapheresis with plasma exchange has increased survival in patients with thrombotic thrombocytopenic purpura (TTP) from <10% to 80%. More than 30% of patients with TTP have at least 1 relapse within 2 years. Treatment with rituximab normalizes ADAMTS13 and induces durable remissions in >90% of patients with refractory or relapsing TTP. Rituximab is increasingly used in the upfront setting with evidence of improved rates of remission and disease-free interval.4,5 

The standard dosing regimen for rituximab is 375 mg/m2 weekly for 4 weeks, which is the dose adopted from regimens developed to treat of non-Hodgkin lymphoma. In autoimmune conditions with a lower total lymphocyte mass, an efficacious dose of rituximab is likely less than what is administered for the treatment of lymphoma. Lower doses of rituximab are attractive...

You do not currently have access to this content.